AAAdrian Andres Aguilar-Morgan

Adrian Andres Aguilar-Morgan

*This is an algorithmically generated author record based on publicly available information.

Adrian Andres Aguilar-Morgan has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Testosterone Boosters: How Real Are Their Effects?

    by Adrian Andres Aguilar-Morgan, Abraham Morgentaler, Luis Antonio Reyes-Vallejo

    In the past decade, there has been an increased interest in alternative treatments to testosterone (T) and androgen derivatives. This has led to the development of supplements known as “testosterone boosters” ( T-boosters ) or “testosterone enhancers.” The internet is the main source for the purchase of these products with sales reaching millions of dollars. The search for T-boosters is focused on improvement in sexual performance, muscular strength, and increased muscle mass using agents considered “natural,” which are thereby presumed to lack serious adverse effects. Some of these supplements have been used since antiquity. Commercially sold T-boosters nearly always comprise multiple supplements, and none of these combinations have undergone rigorous evaluations, as would be required for regulatory approval for pharmaceutical products. This makes it challenging to evaluate marketing claims. However, a limited scientific literature does exist for the primary individual agents in most T-boosters. The most commonly used agents are Tribulus terrestris , fenugreek, zinc, maca, and ashwaganda (“Indian ginseng”). Those studies form the basis of this review. Although some studies have offered suggestive results indicating possible increases in serum T, the data are inconsistent, and studies differ widely in methods, including supplement dosage. In addition, serious adverse events have been reported. Currently, the existing literature fails to support the use of these products.


  • Open Access

    Effect of polymerized type I collagen in hyperinflammation of adult outpatients with symptomatic COVID-19: a double blind, randomised, placebo-controlled clinical trial

    by Silvia Méndez-Flores, Ángel Priego-Ranero, Daniel Azamar-Llamas, Héctor Olvera-Prado, Kenia Ilian Rivas-Redondo, Eric Ochoa-Hein, Andric Perez-Ortiz, Estefano Rojas-Castañeda, Said Urbina-Terán, Luis Septién-Stute, et al.

    BACKGROUND: Currently, therapeutic options for ambulatory COVID-19 patients are limited. OBJECTIVE: To evaluate the safety, efficacy and effect of the intramuscular administration of polymerized type I collagen (PTIC) on hyperinflammation, oxygen saturation and symptom improvement in adult outpatients with symptomatic COVID-19. DESIGN: Double-blind, randomised, placebo-controlled clinical trial of PTIC vs placebo. SETTING: Single Third-level hospital in Mexico City (Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán) PARTICIPANTS: Eighty-nine adult participants with a confirmed COVID-19 diagnosis and symptom onset within the 7 days preceding recruitment were included from August 31, 2020 to November 7, 2020 and followed for 12 weeks. Final date of follow-up was February 4, 2021. INTERVENTIONS: Patients were randomly assigned to receive either 1.5 ml of PTIC intramuscularly every 12 h for 3 days and then every 24 h for 4 days (n=45), or matching placebo (n=44). MAIN OUTCOMES AND MEASURES: The primary outcome was a mean reduction of at least 50% in the level of IP-10 compared to baseline. The secondary outcomes were mean oxygen saturation ≥92% while breathing ambient air and duration of symptoms. RESULTS: Of 89 patients who were randomised, 87 (97.8%) were included in an intention-to-treat analysis; 37 (41.6%) were male and mean age was 48.5±14.0 years. The IP-10 levels decreased 75% in the PTIC group and 40% in the placebo group vs baseline. The comparison between treatment vs placebo was also statistically significant ( P= 0.0047). The IL-8 (44%, P= 0.045), M-CSF (25%, P= 0.041) and IL-1Ra (36%, P= 0.05) levels were also decreased in the PTIC group vs baseline. Mean oxygen saturation ≥92% was achieved by 40/44 (90%), 41/42 (98%) and 40/40 (100%) of participants that received PTIC at 8, 15 and 97 days of follow-up vs 29/43 (67%), 31/39 (80%) and 33/37 (89%) of patients treated with placebo ( P =0.001). The unadjusted accelerated failure time model showed that patients treated with PTIC achieved the primary outcome 2.70-fold faster ( P P <0.0001). Symptom duration in patients treated with PTIC was reduced by 6.1±3.2 days vs placebo. No differences in adverse effects were observed between the groups at 8, 15 and 97 days of follow-up. CONCLUSIONS: In this study, treatment with PTIC down-regulated IP-10, IL-8, M-CSF and IL-Ra levels, which could explain the PTIC effect on the higher proportion of patients with mean oxygen saturation readings ≥92% and a shorter duration of symptoms as compared to patients treated with placebo. Although results are encouraging, larger randomised trials are needed. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04517162